Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…
ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization,…
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
OAK BROOK, Ill., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Ingenio Care, Inc., an AI-driven digital health company, today announced the…
BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced…
October 17, 2025 16:05 ET | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding…
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…